EcoDrugPlus

Protein Kinase D3

Ensembl ID : ENSSFOG00015001426
Gene Symbol: PRKD3
3 Cross references
201 Possible Orthologues:

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSSFOG00015000703
Gene Symbol: PRKDC
1 Cross references
184 Possible Orthologues:

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSSFOG00015001288
Gene Symbol: PPP3CA
3 Cross references
233 Possible Orthologues:

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSSFOG00015018908
Gene Symbol: PPP3CA
3 Cross references
233 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSSFOG00015009767
Gene Symbol: PTK2
3 Cross references
164 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSSFOG00015016572
Gene Symbol: PTK2B
3 Cross references
200 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSSFOG00015017898
Gene Symbol: PTPRB
3 Cross references
201 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSSFOG00015005286
Gene Symbol: PTPRB
3 Cross references
201 Possible Orthologues:

Protein-Tyrosine Kinase 2-Beta-Like

Ensembl ID : ENSSFOG00015019535
Gene Symbol: LOC108924101
3 Cross references
195 Possible Orthologues:

Protein-Tyrosine Kinase 6-Like

Ensembl ID : ENSSFOG00015020718
Gene Symbol: LOC108926388
2 Cross references
107 Possible Orthologues:

Proteinase-Activated Receptor 1-Like

Ensembl ID : ENSSFOG00015023476
Gene Symbol: LOC108938028
3 Cross references
325 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Src

Ensembl ID : ENSSFOG00015021140
Gene Symbol: LOC108939128
3 Cross references
259 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).